Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13G/A for Ikena Oncology, Inc. Common Stock (IKNA).
- Disclosed ownership: 3.6%.
- Date of event: 31 Dec 2024.
GILEAD SCIENCES, INC. - 31 Dec 2024 SCHEDULE 13G/A Report for Ikena Oncology, Inc. Common Stock (IKNA)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- GILEAD SCIENCES INC
- Security
- Ikena Oncology, Inc. Common Stock
- Symbol
- IKNA
- Shares outstanding
- 42,258,667 shares
- Disclosed Ownership
- 1,521,312 shares
- Ownership
- 3.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2025, 16:22:08 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 3.6% ownership in Ikena Oncology, Inc. Common Stock (IKNA) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2025, 16:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES INC | 3.6% | 1,521,312 | 1,521,312 | 0 | /s/ Andrew Dickinson | Andrew Dickinson, Chief Financial Officer |